Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin

Details for Australian Patent Application No. 2011221389 (hide)

Owner AlcaSynn Pharmaceuticals GmbH

Inventors Schmidhammer, Helmut

Agent Griffith Hack

Pub. Number AU-A-2011221389

Parent 2005239831

Filing date 8 September 2011

Wipo publication date 29 September 2011

International Classifications

A61K 31/485 (2006.01) - Morphinan derivatives, e.g. morphine, codeine

A61P 1/00 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 17/00 (2006.01) Drugs for dermatological disorders

A61P 17/06 (2006.01) Drugs for dermatological disorders

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 27/06 (2006.01) Drugs for disorders of the senses

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/08 (2006.01) Drugs for immunological or allergic disorders

Event Publications

22 September 2011 Complete Application Filed

29 September 2011 Application Open to Public Inspection

  Published as AU-A-2011221389

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011221390-Beamspace-time coding based on channel quality feedback

2011221388-Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents